January 2026 Research Update

This month added one clear human trial result suggesting that diazoxide choline extended-release (DCCR), a medicine studied for intense hunger in Prader-Willi syndrome, led to smaller increases in hunger scores and less weight gain than placebo over 16 weeks. Alongside that, an earlier-stage drug program (RGH-706) reported weight loss in mice and noted that early human studies in obesity are completed, with an exploratory study in Prader-Willi syndrome underway, but without patient results reported yet. Together, these studies strengthen the sense that appetite and weight pathways remain a central target in PWS research, with one treatment showing measurable short-term differences in a controlled trial and another still in the early pipeline. [1] [2]

In the randomized withdrawal study, people who continued DCCR had a smaller worsening on a caregiver-rated hunger questionnaire than those switched to placebo, and the DCCR group also showed less weight gain during the same period. Side effects were reported at similar rates between groups, and no serious side effects were reported in the DCCR arm in this study. This helps put the focus on outcomes that families often track day to day, like food-seeking behavior and weight change, while also showing what was measurable over a 16-week window. [1]

RGH-706 was described as a drug that blocks the MCHR1 receptor, with weight loss reported after 14 days in a mouse obesity model. The paper also states the compound has progressed through Phase I studies in people with obesity and into an exploratory Phase II study in Prader-Willi syndrome, but it did not provide results in PWS participants. For patients, this is best understood as a sign of active drug development rather than evidence of benefit in PWS at this time. [2]

For families looking for updates on treatments for hyperphagia (severe, persistent hunger), the most immediately relevant evidence this month is the controlled trial showing DCCR had smaller increases in hunger scores and less weight gain than placebo over 16 weeks. This does not by itself answer longer-term questions, such as how durable the effect is over many months or years, because the reported window was short. The RGH-706 report mainly matters as early research progress, because it shares animal results and development stage but not PWS clinical outcomes yet.

Two studies this month looked at practical, everyday health issues in Prader-Willi syndrome: sleep-disordered breathing and dietary intake. The sleep study suggests that very young children were not more likely than older children to newly develop obstructive or central sleep apnea after starting growth hormone, even though older children had more severe obstructive sleep apnea before treatment. The nutrition study found a consistent pattern of energy intake being far above recommended targets in a cohort of adolescents and adults with PWS, while many other parts of diet quality were closer to national guideline patterns, with a few common nutrient gaps. [3] [4]

In the sleep study using overnight sleep testing before and after growth hormone, older children (age 2 years and up) showed more severe obstructive sleep apnea before treatment than children under 2 years. After growth hormone, new obstructive sleep apnea occurred at similar rates in the younger and older age groups, and changes in central sleep apnea (new cases or resolution) were also not worse in the youngest children. In plain terms, this study adds reassurance that the youngest children were not singled out as higher risk for new sleep apnea after growth hormone in this dataset, while also highlighting that sleep apnea can be present even before treatment, especially in older children. [3]

In the Australian dietary assessment of adolescents and adults enrolled in an exercise trial, reported energy intake was about 85% to 90% above recommended levels on average. Even with that high energy intake, overall diet patterns were described as aligned with national guidelines, and most participants met many essential nutrient recommendations, but saturated fat and sodium were high and calcium, iron, and magnesium were often low. The study also reported that people above a healthy weight range were less likely to meet the PWS energy target, and that supervised residences had higher vegetable intake but lower fruit variety. [4]

This theme mainly adds understanding about monitoring and daily management challenges, rather than introducing a new treatment effect. The sleep findings may matter now because they frame what families and clinics may already be watching for: sleep apnea can vary by age and can change after starting growth hormone, but the youngest children were not shown to have a higher rate of new sleep apnea in this study. The nutrition findings may matter now because they highlight a common pattern to be aware of in PWS research cohorts: overall diet quality can look reasonable on some measures while total energy intake is still far above target, with repeated gaps in minerals like calcium and magnesium and repeated excesses like saturated fat and sodium. These results do not prove what causes weight differences, but they clarify what challenges are showing up in real-world eating patterns.

This month included case reports showing that health issues in and around Prader-Willi syndrome can be more than one diagnosis at once, and that unexpected acute illnesses can occur. One report described a child with PWS who also had a separate inherited cause of severe hearing loss, and the other described a serious pelvic infection in a young girl with suspected PWS that recovered fully after treatment. Alongside these single-patient reports, a caregiver study of pharmacogenomic testing (testing genes that can affect medication response) found that medication changes were rare, but many caregivers still valued having information for possible future medication decisions. [5] [6] [7]

In the hearing-loss case, a male infant with PWS was found to also have two TMC1 gene variants causing congenital severe-to-profound sensorineural hearing loss, meaning the child had a dual genetic diagnosis. After sequential cochlear implants and rehabilitation, four years of follow-up described improvements in hearing-related skills and language development. The main message is not that this is typical in PWS, but that additional genetic conditions can coexist and may explain symptoms that are not fully accounted for by PWS alone. [5]

In the acute illness case, a prepubertal girl with severe obesity and suspected PWS was found during surgery to have a ruptured tubo-ovarian abscess caused by Group A Streptococcus, after she initially presented in a way that suggested appendicitis. She recovered fully after surgical drainage and targeted antibiotics. For readers, this mainly underscores that urgent abdominal symptoms can sometimes have uncommon causes, and the report documents one such rare scenario rather than a typical PWS complication. [6]

In the pharmacogenomic testing study, only one caregiver reported a medication change after receiving test results during the follow-up period, while most caregivers said the most valuable part was learning about how future medications might work. By 6 months, about 36.59% of caregivers had shared results with their child's health care providers. This paints a picture of PGx testing being experienced more as "information for later" than as something that immediately changes medications in routine life for many families. [7]

This theme is mainly about what can be learned from individual experiences and early-use tools, not about general rules for everyone with PWS. The dual-diagnosis hearing-loss case supports the idea that when a symptom is unusually severe or has a different pattern than expected, additional genetic explanations can sometimes be found, and targeted interventions may then be possible, but this is based on a single child. The tubo-ovarian abscess case is also a single-patient reminder that rare but treatable acute conditions can happen and may initially look like more common problems. The pharmacogenomic testing study suggests that, for many families, medication-gene testing may not lead to immediate medication changes, but it can still feel useful as planning information, and it remains uncertain how often it changes outcomes in PWS care.